Merck Cuts Sales Forecast as Sales of Top Drugs Fall
This article is for subscribers only.
Merck & Co., the second-biggest U.S. drugmaker, saw sales of two top drugs fall and cut its full-year revenue forecast.
The company’s third-quarter sales fell 4 percent to $10.6 billion. Full-year revenue will be at most $42.8 billion, Merck said in a statement today, a decline from the company’s July projection of $43.2 billion.